ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
09/16/201616:26:00Valeant Comments On Discount And Rebate Program For Nitropress...
09/16/201616:26:00Valeant Comments On Discount And Rebate Program For Nitropress...
09/11/201623:20:00Starboard Value Takes 4.6% Stake in Perrigo
09/06/201617:00:00Valeant And Progenics Announce The U.S. Commercial Launch Of...
09/06/201617:00:00Valeant And Progenics Announce The U.S. Commercial Launch Of...
09/01/201616:44:22Initial Statement of Beneficial Ownership (3)
08/30/201617:00:00Valeant Pharmaceuticals To Participate In September Healthcare...
08/30/201617:00:00Valeant Pharmaceuticals To Participate In September Healthcare...
08/30/201610:15:00Orexigen in Canadian Marketing Pact With Valeant for Diet Drug
08/24/201618:20:00Mylan Faces Scrutiny Over EpiPen Price Increases
08/24/201616:45:41Statement of Changes in Beneficial Ownership (4)
08/24/201616:34:17Initial Statement of Beneficial Ownership (3)
08/23/201617:03:35Current Report Filing (8-k)
08/23/201616:56:43Current Report Filing (8-k)
08/23/201603:03:00New CFO Tops Off Shake-Up At Valeant -- WSJ
08/23/201601:00:00Pharming Convene an Extraordinary General Meeting of Shareholders
08/23/201601:00:00Pharming Convene an Extraordinary General Meeting of Shareholders
08/22/201615:32:00Valeant Names Zoetis Executive as Financial Chief--Update
08/22/201615:30:00Valeant Names Zoetis Executive as Financial Chief--Update
08/22/201610:44:00Valeant Names Zoetis Executive as Financial Chief--Update

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad